Dawn Hill
About Dawn Hill
Dawn Hill serves as the Chief Clinical Operations Officer at BridgeBio, where she has worked since 2018. She has extensive experience in clinical operations, having held leadership roles at several pharmaceutical companies including OncoMed Pharmaceuticals and Omnicare.
Work at BridgeBio
Dawn Hill serves as the Chief Clinical Operations Officer at BridgeBio, a position she has held since 2018. In this role, she manages clinical operations for BridgeBio Oncology Therapeutics affiliates, including Navire Pharma and TheRas Inc. Additionally, she oversees clinical operations for QED Therapeutics' skeletal dysplasia programs. Her leadership focuses on ensuring efficient and effective clinical trial management and operational excellence within the organization.
Previous Experience in Clinical Operations
Before joining BridgeBio, Dawn Hill held several significant positions in clinical operations. She was the Executive Director of Clinical Operations at OncoMed Pharmaceuticals from 2011 to 2018, where she contributed to the company's clinical development efforts. Prior to that, she served as Vice President of West Coast Business Operations and Clinical Services at Omnicare, a CVS Health company, from 2004 to 2010. Her earlier experience includes roles as Vice President of Global Project Management at Clinimetrics and Clinical Research Associate positions at Chiron Corporation and Roche.
Education and Expertise
Dawn Hill studied Biochemistry at the University of California, Davis, where she earned a Bachelor of Science degree. She also attended Baden Senior School at CFB Baden–Soellingen in Germany. Her educational background provides a strong foundation for her extensive career in clinical operations and project management within the pharmaceutical and biotechnology industries.
Career Timeline
Dawn Hill's career spans several decades in the clinical operations field. She began her professional journey at Roche as a Clinical Research Associate from 1991 to 1995, followed by a similar role at Chiron Corporation from 1995 to 1996. She then progressed to various leadership positions, including Vice President roles at Clinimetrics and Omnicare, before becoming Executive Director at OncoMed Pharmaceuticals. Her diverse experience has equipped her with a comprehensive understanding of clinical development processes.